That’s a large number even for a CEO with outsize compensation, but few shareholders would quibble with the option award.

Palantir Technologies, the most expensive stock in the S&P 500 index, might also be one of a handful of companies capable of performing one of the most crucial tasks in the current economy.

Shares of Sagimet Biosciences were up as much as 12% after encouraging clinical trial results for its acne treatment.